News
In brief
BMJ 2000; 320 doi: https://doi.org/10.1136/bmj.320.7246.1358/b (Published 20 May 2000) Cite this as: BMJ 2000;320:1358FDA backs Herceptin: The US Food and Drug Administration says that despite the recent findings that Genentech's breast cancer drug Herceptin (trastuzumab) was linked to the deaths of 15 patients and 47 adverse reactions, the drug's benefits still outweigh its risks.
Mobile phones might pose risk to children: The UK government is …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.